Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P180043/S010

QIAGEN therascreen FGFR RGQ RT-PCR Kit

QIAGEN GmbH · Decision date May 6, 2026

FDA DECISIONP180043/S010

What did the FDA approve?

FDA records P180043/S010 as a supplement to PMA P180043, with the supplement type “Real-Time Process”. The recorded decision is approval, dated May 6, 2026.

FDA approval order statement

Approval for a minor material change which would replace the BSA (Bovine Serum Album) in the PCR Master Mix tubes with a recombinant Human Serum Albumin (rHSA).
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Medical Genetics
Decision date
May 6, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P180043/S010
Regulatory pathway
PMA supplement
Applicant
QIAGEN GmbH
Product code
OWD
Decision code
APPR
Decision date
May 6, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Somatic gene mutation detection system.

Applicant
QIAGEN GmbH
Product code
OWD
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P180043/S007 · Related supplement

    QIAGEN therascreen FGFR RGQ RT-PCR Kit

  2. P180043/S010 received

    Application receipt date recorded by FDA.

  3. P180043/S010 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P180043. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P180043

Product / regulatory recordCompanyPathwayDecision dateSource
QIAGEN GmbHPMA supplementOct 3, 2025FDA

Explore the linked device profile

Other records with product code OWD

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA
RochePMA supplementNov 4, 2026FDA
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
RochePMA supplementOct 27, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

QIAGEN GmbH

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Qiagen Strasse 1, Hilden, 40724

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records